Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | -647K | -668K | 0 | 0 |
| Operating Income | -89M | -71M | -50M | -41M |
| EBITDA | -88M | -70M | -50M | -41M |
| Net Income | -75M | -62M | -47M | -40M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$37.30
+1.55% today
1Y Change
+155.32%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sionna Therapeutics, Inc. (SION) is a Healthcare stock with a market cap of $1.76B and listed on NASDAQ. The stock last traded around $37.30 and up 155.3% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -34.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -34.3%, free cash flow -26.2% with operating margin 0.0% and ROIC -28.2%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SION price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SION
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SION Max Drawdown
-27.07%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SION and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$40.2M
+14.9% YoY
Free Cash Flow
-$37.9M
+15.3% YoY
Revenue Growth
+0.0%
EPS Growth
-34.3%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | -647K | -668K | 0 | 0 |
| Operating Income | -89M | -71M | -50M | -41M |
| EBITDA | -88M | -70M | -50M | -41M |
| Net Income | -75M | -62M | -47M | -40M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & Equivalents | 58M | 38M | 39M | 55M |
| Total Assets | 326M | 186M | 52M | 87M |
| Total Liabilities | 19M | 349M | 167M | 157M |
| Shareholder Equity | 307M | -164M | -115M | -70M |
| Total Debt | 9M | 10M | 10M | 0 |
| Net Debt | -50M | -28M | -28M | -55M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
36M
+17.5% YoY
Capital Expenditures
2M
-67.9% YoY
Free Cash Flow
38M
+15.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-22.9%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.